Latest news with #AliElGhamrawy
Zawya
12-05-2025
- Health
- Zawya
Egypt hosts 170 pharmaceutical factories, 11 with international accreditation: EDA
Egypt is home to 170 pharmaceutical factories, 11 of which are internationally accredited by leading organizations such as the World Health Organization (WHO) and the European Medicines Agency (EMA), according to Dr. Ali El-Ghamrawy, Chairperson of the Egyptian Drug Authority (EDA). Speaking at the 8th Pharma Forum—one of the Arab world's most prominent pharmaceutical events—El-Ghamrawy emphasized that public health challenges today are increasingly complex, interconnected, and demand a multi-sectoral 'One Health' approach. The forum was held under this theme and sponsored by the EDA and the Egyptian Authority for Unified Procurement. 'These challenges extend beyond traditional medicine and include antimicrobial resistance, food safety, medicine supply sustainability, and ecosystem protection,' El-Ghamrawy said. 'They require integrated solutions and collective national and international action.' He highlighted that Egypt has made significant strides in strengthening its pharmaceutical industry, achieving a domestic self-sufficiency rate of 91.3%. The country now operates 2,370 production lines—986 of which are dedicated to pharmaceutical manufacturing. These capabilities, he noted, are central to Egypt's efforts to secure stable medicine supplies and enhance its resilience against global supply disruptions. El-Ghamrawy stressed that the EDA has launched ambitious initiatives to localize pharmaceutical production, both through domestic innovation and international partnerships aimed at technology transfer. So far, Egypt has successfully localized 129 pharmaceutical products that previously cost the country $633.7m in annual imports. He added that the EDA is targeting the local production of around 400 active pharmaceutical ingredients (APIs), spanning 30 therapeutic categories, which currently account for approximately $1.57bn in import costs. In support of these efforts, El-Ghamrawy announced that the Authority is preparing a new package of investment incentives designed to support national pharmaceutical manufacturers and create a regulatory environment that promotes innovation and industry leadership. 'This year's conference focuses on a key national priority—localizing the pharmaceutical industry—part of Egypt's strategic vision for regional and global leadership,' he said. He also underscored Egypt's recent achievement of reaching WHO's 'Maturity Level 3' in the regulation of medicines and vaccines—the first African country to attain this status, and one of only 18 countries globally to do so. 'This reflects the strength and stability of Egypt's pharmaceutical regulatory system and positions the Egyptian Drug Authority as a trusted reference body both regionally and internationally,' El-Ghamrawy added. He also praised the critical role of Egyptian researchers and scientists in bridging the gap between research and industrial application—from discovering active compounds to developing advanced manufacturing processes. Their work, he said, is essential for enhancing supply chains, reducing dependency on imports, and reinforcing national pharmaceutical security. Citing global pharmaceutical R&D trends, El-Ghamrawy referenced recent data showing that the United States leads with 11,455 pharmaceutical products developed from discovery to production, followed by China with 7,032, and South Korea with 3,386. He concluded by affirming Egypt's readiness to follow in the footsteps of these global leaders, leveraging its scientific expertise and growing manufacturing base to expand its global footprint in the pharmaceutical sector. © 2024 Daily News Egypt. Provided by SyndiGate Media Inc. ( Daily News Egypt
Zawya
10-02-2025
- Health
- Zawya
Servier Egypt celebrates jubilee with new production line, cancer programme
Egypt - Servier Egypt, part of the global Servier Group, has commemorated its 70th anniversary with the opening of a new production line and the launch of the 'Access Cancer Treatment (ACT) for Children' initiative. The announcements were made at an event attended by Ali El Ghamrawy, Head of the Egyptian Drug Authority, and Hesham Stait, Head of the Egyptian Authority for Unified Procurement. Stait highlighted the importance of public-private partnerships for Egypt's Vision 2030. Servier Egypt has been operating in the country for over 50 years, focusing on sustainable development and access to treatments. It currently produces 25 million boxes of medication annually for Egyptian patients. The company's pharmaceutical site in 6th of October City, one of Servier Group's eight worldwide, was established in 1994. Production has grown to 25 million boxes annually, with 90% for the local market and 10% exported to nine countries in Africa and the Middle East. Servier has invested over EGP 1.6 billion in its Egyptian operations, including EGP 370 million in 11 projects focused on capacity building, corporate social responsibility, and digital procedures. These include solar panels, a wastewater treatment system, and a new packaging line. The company aims to produce 50 million boxes annually by 2030, increasing exports and partnerships to position Egypt as a regional pharmaceutical hub. 'This milestone reaffirms our long-standing commitment to Egypt's Vision 2030,' said Samy Sinnuqrut, General Manager of Servier Egypt. 'By investing in local production and innovation, we aim to enhance patient access to advanced treatments while contributing to Egypt's economic and healthcare priorities.' Servier Egypt offers 34 medicines, including treatments for cardio-metabolism, venous diseases, and oncology, with plans to introduce two more oncology treatments. The ACT for Children initiative, in partnership with other organisations, addresses childhood cancer disparities. 'Through ACT for Children, we aim to create long-term infrastructure and sustainable healthcare solutions that ensure children everywhere have access to the care and treatments they need,' Sinnuqrut said. 'This is central to our Servier 2030 ambition to make a measurable, positive social impact.' Servier Egypt offers 32 solid dosage form products, along with two specialised oncology medications. © 2024 Daily News Egypt. Provided by SyndiGate Media Inc. (
Daily News Egypt
10-02-2025
- Health
- Daily News Egypt
Servier Egypt celebrates jubilee with new production line, cancer programme
Servier Egypt, part of the global Servier Group, has commemorated its 70th anniversary with the opening of a new production line and the launch of the 'Access Cancer Treatment (ACT) for Children' initiative. The announcements were made at an event attended by Ali El Ghamrawy, Head of the Egyptian Drug Authority, and Hesham Stait, Head of the Egyptian Authority for Unified Procurement. Stait highlighted the importance of public-private partnerships for Egypt's Vision 2030. Servier Egypt has been operating in the country for over 50 years, focusing on sustainable development and access to treatments. It currently produces 25 million boxes of medication annually for Egyptian patients. The company's pharmaceutical site in 6th of October City, one of Servier Group's eight worldwide, was established in 1994. Production has grown to 25 million boxes annually, with 90% for the local market and 10% exported to nine countries in Africa and the Middle East. Servier has invested over EGP 1.6 billion in its Egyptian operations, including EGP 370 million in 11 projects focused on capacity building, corporate social responsibility, and digital procedures. These include solar panels, a wastewater treatment system, and a new packaging line. The company aims to produce 50 million boxes annually by 2030, increasing exports and partnerships to position Egypt as a regional pharmaceutical hub. 'This milestone reaffirms our long-standing commitment to Egypt's Vision 2030,' said Samy Sinnuqrut, General Manager of Servier Egypt. 'By investing in local production and innovation, we aim to enhance patient access to advanced treatments while contributing to Egypt's economic and healthcare priorities.' Servier Egypt offers 34 medicines, including treatments for cardio-metabolism, venous diseases, and oncology, with plans to introduce two more oncology treatments. The ACT for Children initiative, in partnership with other organisations, addresses childhood cancer disparities. 'Through ACT for Children, we aim to create long-term infrastructure and sustainable healthcare solutions that ensure children everywhere have access to the care and treatments they need,' Sinnuqrut said. 'This is central to our Servier 2030 ambition to make a measurable, positive social impact.' Servier Egypt offers 32 solid dosage form products, along with two specialised oncology medications.
Zawya
06-02-2025
- Business
- Zawya
Servier Egypt celebrates Platinum Jubilee with expansion of state-of-the-art production line
Giza, Egypt: Servier Egypt, a leading player in the pharmaceutical industry and part of the global Servier Group, proudly marked its Platinum Jubilee in Egypt with the inauguration of an additional state-of-the-art production line and the launch of a groundbreaking health access program, "Access Cancer Treatment (ACT) for Children." These milestones coincide with the celebration of 70 years of Servier's global legacy. The event was graced by prominent dignitaries, including Dr. Ali El Ghamrawy, Head of the Egyptian Drug Authority, Dr. Hesham Stait, Head of the Egyptian Authority for Unified Procurement. In his remarks, he highlighted the importance of public-private partnerships in achieving Egypt's Vision 2030, particularly in areas like localized production, increased exports, and innovative healthcare solutions. For over five decades, Servier Egypt has been a trusted partner in the nation's healthcare journey, contributing to Egypt's Vision 2030 by prioritizing sustainable development, innovation, and expanding access to life-saving treatments. Today, Servier Egypt produces 25 million boxes for Egyptian patients annually. Servier Egypt's pharmaceutical site, with its two manufacturing facilities located in 6th of October, is one of eight Servier Group pharmaceutical sites worldwide. It was established in 1994 with an initial capacity to produce 5 million boxes annually. Today, the site is celebrating 30 years of serving patients with the highest product quality and safety standards. Volumes have grown year-over-year, reaching 25 million boxes, of which 90% is dedicated to the local market and 10% is exported to nine countries across Africa and the Middle East. In total, Servier has invested more than EGP 1.6 billion in its operations and production capacity in Egypt, of which EGP 370 million are being invested into a specific program, spanning 11 key projects focusing on capacity building, CSR, quality, safety and digital procedures. Extensive parts of this local-talent-led transformation have already been realized, including the installation of solar panels, a wastewater treatment system and a new high-speed packaging line. At the end of the transformation program, the site will mark a significant 2030 milestone of producing 50 million boxes annually. While continuing to meet local healthcare needs, this capacity will open the door to increase Servier Egypt's exports in the region and external partners. These steps perfectly reflect Servier's ambition to position Egypt as a regional hub for high-quality pharmaceutical manufacturing and export excellence. Samy Sinnuqrut, General Manager of Servier Egypt, stated, 'This milestone reaffirms our long-standing commitment to Egypt's Vision 2030. By investing in local production and innovation, we aim to enhance patient access to advanced treatments while contributing to Egypt's economic and healthcare priorities. Our goal is to provide cutting-edge medicines not only to Egypt but also to the wider region.' Servier Egypt offers a diverse portfolio of 34 medicines, addressing a wide range of therapeutic areas to meet the evolving needs of Egyptian patients. The company is a leader in cardio-metabolism and venous diseases (CMVD), providing innovative solutions for hypertension, diabetes, and heart failure. Additionally, Servier has made significant strides in oncology, bringing life-changing treatments for metastatic colorectal cancer and pancreatic cancer to EGYPT—two areas where medical needs are urgent. Our mission does not stop here. We are actively working to bring two more state-of-the-art oncology treatments to Egypt Servier also announced the debut of Access Cancer Treatment (ACT) for Children Initiative, a flagship health access program addressing childhood cancer disparities, in partnership with several organizations. The ACT for Children initiative focuses on providing access to quality medical care, empowering healthcare professionals with advanced skills, and expanding availability of life-saving treatments. 'Through ACT for Children, we aim to create long-term infrastructure and sustainable healthcare solutions that ensure children everywhere have access to the care and treatments they need,' added Sinnuqrut. 'This is central to our Servier 2030 ambition to make a measurable, positive social impact.' About Servier Egypt Servier Egypt is a leading pharmaceutical company with a strong presence in Egypt and a commitment to improving patient health. They offer a comprehensive portfolio of 32 solid dosage form products, along with 2 specialized oncology medications. This diverse range of medicines addresses various therapeutic areas and meets the evolving healthcare needs of Egyptians. For more information, please contact: Asmaa Ghoneim
